The future of CTCL therapy
4 Bekeken
• 08/09/23
0
0
insluiten
administrator
abonnees
Martine Bagot, MD, PhD, Hôpital Saint Louis, Paris, France, suggests how the therapeutic landscape of cutaneous T-cell lymphoma (CTCL) may evolve in the future, with the development of novel monoclonal antibodies, oncogenic peptides, and agents targeting overactivated signaling pathways in CTCL. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
Laat meer zien
Facebook Reacties
SORT BY-
Top Reacties
-
Laatste Reacties